Literature DB >> 27397735

Refocusing the AIM on HDL in the metabolic syndrome.

Robert W McGarrah1.   

Abstract

Entities:  

Keywords:  Cardiovascular risk; HDL subclasses; HDL-C; Lipoprotein fractions

Mesh：

Substances：

Year:  2016        PMID： 27397735      PMCID： PMC5504691          DOI： 10.1016/j.atherosclerosis.2016.06.051

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  28 in total

1.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

Review 2.  Subfractions and subpopulations of HDL: an update.

Authors:  M Rizzo; J Otvos; D Nikolic; G Montalto; P P Toth; M Banach
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

3.  Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.

Authors:  John J Albers; April Slee; Jerome L Fleg; Kevin D O'Brien; Santica M Marcovina
Journal:  Atherosclerosis       Date:  2016-06-11       Impact factor: 5.162

4.  Development of a homogeneous assay for measurement of high-density lipoprotein-subclass cholesterol.

Authors:  Yasuki Ito; Noriyuki Satoh; Takayoshi Ishii; Junko Kumakura; Tsutomu Hirano
Journal:  Clin Chim Acta       Date:  2013-09-19       Impact factor: 3.786

5.  HDL cholesterol efflux capacity and incident cardiovascular events.

Authors:  Anand Rohatgi; Amit Khera; Jarett D Berry; Edward G Givens; Colby R Ayers; Kyle E Wedin; Ian J Neeland; Ivan S Yuhanna; Daniel R Rader; James A de Lemos; Philip W Shaul
Journal:  N Engl J Med       Date:  2014-11-18       Impact factor: 91.245

6.  High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.

Authors:  Samia Mora; Robert J Glynn; Paul M Ridker
Journal:  Circulation       Date:  2013-09-03       Impact factor: 29.690

7.  Beyond Coronary Calcification, Family History, and C-Reactive Protein: Cholesterol Efflux Capacity and Cardiovascular Risk Prediction.

Authors:  Purav Mody; Parag H Joshi; Amit Khera; Colby R Ayers; Anand Rohatgi
Journal:  J Am Coll Cardiol       Date:  2016-05-31       Impact factor: 24.094

8.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

9.  Effects of torcetrapib in patients at high risk for coronary events.

Authors:  Philip J Barter; Mark Caulfield; Mats Eriksson; Scott M Grundy; John J P Kastelein; Michel Komajda; Jose Lopez-Sendon; Lori Mosca; Jean-Claude Tardif; David D Waters; Charles L Shear; James H Revkin; Kevin A Buhr; Marian R Fisher; Alan R Tall; Bryan Brewer
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

10.  High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.

Authors:  Robert W McGarrah; Damian M Craig; Carol Haynes; Z Elaine Dowdy; Svati H Shah; William E Kraus
Journal:  Atherosclerosis       Date:  2016-01-11       Impact factor: 5.162
View more
  1 in total

1.  A Novel Protein Glycan-Derived Inflammation Biomarker Independently Predicts Cardiovascular Disease and Modifies the Association of HDL Subclasses with Mortality.

Authors:  Robert W McGarrah; Jacob P Kelly; Damian M Craig; Carol Haynes; Ryan C Jessee; Kim M Huffman; William E Kraus; Svati H Shah
Journal:  Clin Chem       Date:  2016-11-03       Impact factor: 8.327
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.